Recent studies show that Fadraciclib elicits rapid apoptosis in a panel of AML cell lines in vitro, via the rapid loss of MCL-1 protein expression, and reduces leukaemia burden in xenograft models of MLL (EOL-1) and non-MLL (HL-60) AML, exhibiting superiority over the conventional AML therapeutic cytarabine/ara-C, in this setting (Frame et al., 2020). Here, MCL1 is linked to acute myeloid leukemia.